CTAD 2022 – lecanemab data hold up, with a big but

The numbers behind groundbreaking topline data Eisai had revealed with its Alzheimer’s project lecanemab in the pivotal Clarity-AD trial might shock the most bullish amyloid-beta believers. At worst they show lecanemab to be no better than Biogen’s controversially approved Aduhelm, albeit with less of the Aria-E side effect, the CTAD conference heard last night.